Nouscom will present re-treatment data for Lynch Syndrome at ESMO 2026, highlighting long-term follow-up results that support the progression towards a registration-enabling trial. This data could be pivotal for future treatment options in this patient population.
Long‑term follow‑up reinforces momentum toward registration‑enabling trial
Original title: “Nouscom to present re‑treatment data in Lynch Syndrome at ESMO 2026”